• Photo by Greta Kaul
    Photo by Greta Kaul

    Patently lucrative: the intellectual property that makes big money for the U

    Compounds developed in Robert Vince’s University of Minnesota lab to combat the HIV virus made the University more than $600 million dollars. Read More

  • MS_StevePatterson

    Research Spotlight

    Patterson Group - Multiple Sclerosis

    Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) resulting in damage to the myelin or insulating covers in the brain and spinal cord. Read more about Patterson Group's efforts toward developing a treatment for MS: Click Here

  • Profs Vince and More

    Seeing Alzheimer's disease

    A retinal scan technique, developed by researchers in the University’s Center for Drug Design (CDD), has the potential to detect AD in its early stages, when treatment may still be possible, and also to allow doctors to trace the progress of treatments and help the 100,000 Minnesotans with AD and their families. Read More

  • Photo by Ananya Mishra
    Photo by Ananya Mishra

    UMN technology will aid Alzheimer's detection

    New technology — created by Profs Robert Vince and Swati More from the Center for Drug Design — uses a camera to collect images of light interacting with the retina, which can show the early presence of Alzheimer’s Disease. Read full article on Minnesota Daily: Click Here

Message from the Director

Robert Vince

Robert Vince, PhD

The Center for Drug Design (CDD) was created to combine research and scholarship leading to the development of novel drugs for therapeutic applications, such as HIV, cancer, neurological diseases, dermatological agents, infectious diseases, novel processes, and medical devices. The Center for Drug Design combines the best of academic tradition along with an expectation of innovation and independence, and provides significant value  for our academic and research community.

Research Spotlight

Early Detection of Alzheimer's Disease Using an Eye Examination
retina

For the first time, changes associated with early stages of Alzheimer's Disease were detected in live mice through color-shifts in the light reflected by the retina. For human trials, a simple eye test will be conducted by a trained health professional and several images of the retina will be acquired by an FDA approved camera. The procedure involved is non-invasive and does not depend on any extraneous agents. For more information about volunteering and compensation etc, please Click Here

Meet the Team:
Prof Robert Vince (Director, Center for Drug Design)
Prof Swati More (Assistant Professor, Center for Drug Design)
James Beach, PhD (Research Associate, Center for Drug Design, and CytoViva, Inc., Alabama)

Detecting Alzheimer's with an Eye Exam: Video

Detecting Alzheimer's with an Eye Exam